1. 3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. (September 2015) Authors: Popat, S.; Felip, E.; Cobo, M.; Fulop, A.; Dayen, C.; Trigo, J.M.; Gregg, R.; Waller, C.F.; Gordon, J.; Lorence, R.; Wang, B.; Chand, V.K.; Hirsh, V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S626 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7. (January 2016) Authors: O'Byrne, K.J.; Park, K.; Tan, E.; Zhang, L.; Hirsh, V.; Boyer, M.; Yang, J.C.; Mok, T.; Kim, M.; Massey, D.; Zazulina, V.; Paz-Ares, L. Journal: Lung cancer Issue: Volume 91(2016)Supplement 1 Page Start: S25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7). (February 2017) Authors: Hirsh, V.; Park, K.; Tan, E.H.; Zhang, L.; O'Byrne, K.; Boyer, M.; Yang, J.C.H.; Mok, T.; Lee, K.H.; Lu, S.; Shi, Y.; Kim, S.W.; Laskin, J.; Kim, D.W.; Laurie, S.A.; Kölbeck, K.; Fan, J.; Dodd, N.; Märten, A.; Paz-Ares, L. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. (April 2018) Authors: Melosky, B.; Chu, Q.; Juergens, R.A.; Leighl, N.; Ionescu, D.; Tsao, M.-S.; McLeod, D.; Hirsh, V. Journal: Cancer treatment reviews Issue: Volume 65(2018) Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EP-1163 Can concurrent chemoradiation be delayed by induction chemotherapy to treat stage III NSCLC? a pooled analysis. (April 2015) Authors: Garant, A.; Guilbault, C.; Almajed, M.; Faria, S.; Owen, S.; Duclos, M.; Ofiara, L.; Gruber, J.; Hirsh, V.; Kopek, N. Journal: Radiotherapy and oncology Issue: Volume 115(2015)Supplement 1 Page Start: S632 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. (February 2017) Authors: Schuler, M.; Paz-Ares, L.; Sequist, L.V.; Tan, E.H.; Mok, T.; Hirsh, V.; O'Byrne, K.; Zhang, L.; Yamamoto, N.; Boyer, M.; Shah, R.; Bennouna, J.; Dickgreber, N.J.; De Grève, J.; Love, J.; Märten, A.; Fan, J.; Ehrnrooth, E.; Park, K.; Yang, J.C.H. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗